Stocktoria
Immunome Inc. IMNM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-02
Immunome Inc. statistics & valuation
Market cap$2.3B
P / B3.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -3228.8% | -3382.4% | -781.4% | — | — |
| Net margin | -3060.0% | -3240.4% | -761.9% | — | — |
| FCF margin | -2890.1% | -1304.8% | -59.9% | — | — |
| Return on assets | -31.1% | -121.9% | -71.9% | -153.4% | -42.7% |
| Return on equity | -33.5% | -161.7% | -89.1% | -221.6% | -51.3% |
| Current ratio | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 |
| Revenue growth | -23.2% | -35.5% | — | — | — |
Source: SEC EDGAR filings · CIK 0001472012 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.